| Inventor | Institute |
|---|---|
| Jorgen Fogh, Germain Trempe | Memorial Sloan-Kettering Cancer Center (MSK) |
| SKU: | 161906 |
|---|---|
| Product description: | Calu-3 is a non-small-cell lung cancer cell line that grows in adherent culture and displays epithelial morphology. These cells have constitutively active ErbB2/Her2 due to amplification of the ERBB2 gene. They express wildtype EGFR and mutant K-Ras (G13D). In addition, they harbour mutations in TP53 and CDKN2A genes. The Calu-3 cells are sensitive to erlotinib (EGFR tyrosine kinase inhibitor) and cetuximab (a monoclonal antibody that blocks ligand binding to EGFR and prevents downstream signalling), two commonly used drugs targeting ErbB receptors. These cells are capable of forming tumours in immunocompromised mice. |
| Gender: | Male |
| Cellosaurus ID: | CVCL_0609 |
| Products or characteristics of interest: | Isoenzymes: AK-1, 1; ES-D, 1; G6PD, B; GLO-I, 1-2; Me-2, 1; PGM1, 1; PGM3, 1-2; ES-D, 1; G6PD, B; GLO-I, 1-2; Me-2, 1-2; PGM1, 1-2; PGM3, 1 |
| Cat. #: | 161906 |
|---|---|
| Cancer types: | Lung cancer |
| Organism: | Human |
| Tissue: | Lung |
| Gender: | Male |
| Morphology: | Epithelial |
| Growth properties: | Adherent |
| Primary citation: | Fogh J et al.1977.Journal of the National Cancer Institute. 59: 221-226.PMID: 327080. |
| Storage conditions: | Vapor phase of liquid nitrogen. Storage at -70° C will result in loss of viability. |
|---|---|
| Shipping conditions: | Dry Ice |
| Growth medium: | EMEM suplemented with 10% FBS. |
| Subculture routine: | 1. Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor. 2. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). |
| Temperature: | 37° C |
| Atmosphere: | 95% Air, 5% CO2 |
| Storage medium: | Culture medium 95%; DMSO, 5% |
| Biosafety level: | 1 |
| References: |
Fogh J et al.1977.Journal of the National Cancer Institute. 59: 221-226.PMID: 327080. Cavazzoni A et al. 2007. Cancer Letters. 246: 69-81. PMID: 16616810. Blanco R et al. 2009. Human Mutation. 30: 1199–1206. PMID: 19472407. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.